Patients with high-grade, advanced-stage CRC, accompanied by lymph node metastasis and lymphovascular invasion, and who demonstrate HER2/neu overexpression are potential candidates for monoclonal antibody-based targeted therapy. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.